CD40LG and COVID-19: In contrast to IgM antibodies, IgG antibodies specifically directed against the spike protein of SARS-CoV-2 persist relatively stable over time as described by Dan JM et al., who found a percentage of 90% spike IgG-positive convalescents half a year after COVID-19 [26].